AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
fallback

Sitaaim-M Tablet

Prescription Icon
Prescription Required

Marketer

Metcure Remedies Pvt Ltd

Salt Composition

Sitagliptin (50mg) + Metformin (500mg)

Overview Sitaaim-M Tablet

Diabexe Duo tablets combine two medications to effectively manage elevated blood glucose in individuals with type 2 diabetes. This dual action helps prevent serious diabetic complications like kidney disease and vision loss, and may lessen the risk of cardiovascular events such as heart attack or stroke. Diabexe Duo may be used independently or in conjunction with other anti-diabetic therapies. Optimal results are achieved with a balanced diet and regular physical activity. Dosage is individualized based on your health status, blood sugar readings, and other medications. Consuming it with meals minimizes gastrointestinal discomfort. Consistent daily dosing at the same time maximizes therapeutic benefits; discontinuation should only occur under physician guidance. Adherence to your prescribed diet and exercise plan is crucial for successful diabetes control. Your lifestyle significantly impacts your diabetes management. Commonly reported side effects include nausea, vomiting, diarrhea, stomach upset, headache, and sore throat. Low blood sugar (hypoglycemia) is a potential adverse effect, particularly when combined with insulin or sulfonylureas; learn how to identify and manage this. This medication isn't suitable for all patients. Prior to commencing treatment, inform your physician of any history of kidney, liver, or heart disease, pancreatic issues, or significant alcohol consumption. Pregnant or lactating individuals require medical consultation before use. Certain medications can interact with Diabexe Duo; disclose all your medications to ensure safe use. Alcohol should be limited due to its blood glucose-lowering effect. Your doctor will monitor your kidney function and blood sugar levels throughout treatment.

Primary Ingredients of Sitaaim-M Tablet

The provided text is "undefined," so no rephrasing is possible.

Uses of Sitaaim-M Tablet

Managing type 2 diabetes

Major Benefits of Sitaaim-M Tablet:

Consume this medication precisely as prescribed by your physician, adhering to both dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Sitaaim-M tablets should be administered with a meal.

Common Side effects of Sitaaim-M Tablet:

  • Decreased appetite
  • Vomiting
  • Upper respiratory tract infection
  • Hypoglycemia (low blood glucose level)
  • Abdominal bloating
  • Nausea
  • Diarrhea

How to use Sitaaim-M Tablet:

Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and duration. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Sitaaim-M should be administered with a meal.

How Sitaaim-M Tablet works:

Sitaaim-M tablets contain sitagliptin and metformin, working synergistically to manage blood glucose levels. Sitagliptin enhances insulin production by the pancreas, improves insulin utilization, and diminishes hepatic glucose output. Metformin, a biguanide, reduces liver glucose production, slows intestinal glucose absorption, and boosts insulin sensitivity. This combined action leads to superior glycemic control.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining Sitaaim-M Tablet and alcohol is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Use of Sitaaim-M Tablet during pregnancy may pose risks. While human research is scant, animal studies indicate potential harm to a developing fetus. A physician will assess the potential advantages against the risks before prescribing. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

The use of Sitaaim-M Tablet while breastfeeding is likely inadvisable. Available human data indicates a potential for the medication to transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by excessively high or low blood sugar levels. Refrain from driving if such symptoms manifest.

KidneyKidneyCAUTION

Exercise caution when administering Sitaaim-M Tablets to individuals with impaired renal function; dosage modification may be necessary. Consult a physician for guidance. Sitaaim-M Tablets are contraindicated in patients exhibiting severe kidney disease. Routine monitoring of kidney function is recommended during treatment.

LiverLiverUNSAFE

The use of Sitaaim-M Tablets is potentially hazardous for individuals with hepatic impairment and should be omitted. Medical advice is recommended.

What if you forget to take Sitaaim-M Tablet :

Should you forget a Sitaaim-M Tablet dose, administer it promptly. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.

Facts to Know About Sitaaim-M Tablet

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Sitaaim-M Tablet

Sitaaim-M Tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Prolonged Sitaaim-M Tablet use can lead to vitamin B12 deficiency by impairing its absorption. This deficiency, if left untreated, may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and balance problems), urinary issues, and cognitive changes. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Sitaaim-M Tablet may cause common side effects including low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis can occur. Prolonged use may also result in vitamin B12 deficiency.
Sitaaim-M Tablets are contraindicated in patients with known hypersensitivity to any ingredient. Avoid use in patients with severe renal or hepatic impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitaaim-M Tablet and alcohol is unsafe and may heighten the risk of lactic acidosis.
Store this medication in its original, tightly closed container, as directed on the label or packaging. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitagliptin/Metformin (like Sitaaim-M) can cause lactic acidosis, a serious, potentially life-threatening buildup of lactic acid in the blood (also called MALA—Metformin-associated lactic acidosis). This is a rare side effect, but it's why this medication is avoided in people with kidney disease, the elderly, or those who drink heavily. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and slow heart rate. If you experience these, stop taking Sitagliptin/Metformin and seek immediate medical attention.
Sitaaim-M Tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This combination improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin increases insulin release by inhibiting DPP-4. This medication is not suitable for individuals under 18.
Sitaaim-M Tablet may cause common side effects including low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Sitaaim-M Tablets are contraindicated in patients with allergies to any ingredient or excipient. This medication should also be avoided by those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitaaim-M tablets with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin/Metformin (Sitaaim-M) can cause lactic acidosis, a serious medical emergency resulting from high blood lactic acid levels (also known as Metformin-associated lactic acidosis, or MALA). This rare side effect necessitates avoiding Sitaaim-M in patients with kidney disease, older adults, or those who consume excessive alcohol. Symptoms include muscle pain or weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, stop taking Sitaaim-M and seek immediate medical attention.
Prolonged Sitaaim-M Tablet use can lead to vitamin B12 deficiency by hindering its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, and urinary issues), and cognitive changes, including balance problems (ataxia). To mitigate these risks, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, following the storage instructions on the label. Discard any unused medication and ensure it's inaccessible to children, pets, and others.
Sitaaim-M Tablets combine sitagliptin and metformin to manage type 2 diabetes in adults. This medication improves blood sugar control when used with diet and exercise. Metformin reduces liver glucose production and enhances insulin sensitivity, while sitagliptin boosts insulin release by inhibiting DPP-4. This combination is unsuitable for individuals under 18.
Sitaaim-M Tablet may cause common side effects including low blood sugar (hypoglycemia), altered taste, nausea, stomach pain, diarrhea, headache, and upper respiratory infections. Rare but serious side effects such as lactic acidosis may occur. Prolonged use can also result in vitamin B12 deficiency.
Sitaaim-M Tablets are contraindicated in patients with known hypersensitivity to any ingredient. Avoid use in patients with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis.
Combining Sitaaim-M Tablet with alcohol is unsafe and may heighten the risk of lactic acidosis.
Sitagliptin-Metformin (Sitaaim-M) can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as Metformin-associated lactic acidosis, or MALA). This rare side effect necessitates avoiding Sitaaim-M in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Sitaaim-M and seek immediate medical attention.
Prolonged Sitaaim-M Tablet use can lead to vitamin B12 deficiency by interfering with its absorption. This deficiency may cause anemia, nerve damage (manifesting as tingling, numbness in extremities, weakness, urinary issues, cognitive changes, and ataxia), if left unaddressed. To mitigate this risk, annual supplemental vitamin B12 is recommended by some researchers.
Store this medication in its original, tightly closed container, as directed on the label. Discard any unused medication and keep it out of reach of children, pets, and others.
Sitaaim-M Tablet
190
MRP 220
13% off